Graham Kelly, CEO, Noxopharm discusses the company's lead clinical asset, Veyonda, a first-in-class chemotherapy and radiation enhancer that has immuno-oncology properties.  Veyonda has potential utility across solid tumors and boosts the effect of radiation therapy 2-3x in cancer cells.  It has already shown positive results in patients with metastatic castrate-resistant prostate cancer. #oncology #prostatecancer  #radiation #chemotherapy @Noxopharm Noxopharm